|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00512 GRAND PHARMA
Nominal 
7.670 +0.480 (+6.676%) Ranking Overview
Ranking based on 1 research report(s)
Average Ranking 2.00
|
Strong Buy (1)
0
|
Buy (2)
1
|
Hold (3)
0
|
Sell (4)
0
|
Strong Sell (5)
0
|
Previous Financial Performance
| Financial Year | 12/2024 | EPS | 70.49 HKD (cts) | |
| Net Profit | 2,468.38 HKD (MIL) | DPS | 26.00 HKD (cts) |
Consolidation Estimation
| Financial Year | Profit / (Loss) (HKD (MIL)) |
EPS/ ((LPS)(HKD (cts)) |
DPS (HKD (cts)) |
Net Asset Value per Share (HKD) |
Highest (HKD (MIL)) |
Lowest (HKD (MIL)) |
| 2025 | 2,078.95 | 59.00 | -- | 2,078.95 | 2,078.95 | |
| 2026 | 2,346.78 | 66.00 | -- | 2,346.78 | 2,346.78 | |
| 2027 | 2,722.83 | 77.00 | -- | 2,722.83 | 2,722.83 |
Profit Estimation
| Profit Estimation | Profit / (Loss) (HKD (MIL)) |
EPS*/ (LPS) (HKD (cts)) |
DPS * (HKD (cts)) |
Broker | Ranking | Target Price* (HKD) |
Update Date | |
| 2025 | 2,078.95 | 59.00 | -- | GUOYUAN SEC | Buy | 11.88 | 12/12/2025 | |
| 2026 | 2,346.78 | 66.00 | -- | GUOYUAN SEC | -- | -- | 12/12/2025 | |
| 2027 | 2,722.83 | 77.00 | -- | GUOYUAN SEC | -- | -- | 12/12/2025 | |
| Remarks: | Average rating ranges from 1 to 5. The lower the figure, the higher the rating and the vice versa. |
| *EPS, DPS and Estimated Price would be adjusted upon Consolidation, Split and Bonus Issue | |
| Real time quote last updated: 06/03/2026 18:00 | |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD 1,169,019 |
| %Change | -24.964% |
| EPS / (LPS) | HKD 0.334 |
| NBV Per Share ($) | HKD 4.833 |